N-[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl][(4-(4-pyridyloxy)phenyl)amino]carboxamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[4-chloro-2-methoxy-5-(trifluoromethyl)phenyl][(4-(4-pyridyloxy)phenyl)amino]carboxamide
• 英文别名: 1-[4-Chloro-2-methoxy-5-(trifluoromethyl)phenyl]-3-(4-pyridin-4-yloxyphenyl)urea
• 化学式: C₂₀H₁₅ClF₃N₃O₃
• 分子量: 437.806
• InChiKey: PUCLNXKNBLMUAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  72.5
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
  申请人：Miller Scott

  公开号：US20080269265A1

  公开（公告）日：2008-10-30

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
  申请人：Bayer Healthcare LLC

  公开号：US20160015697A1

  公开（公告）日：2016-01-21

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  这项发明涉及使用芳基脲类化合物治疗由异常血管生成或高渗透性过程特征的VEGF诱导信号转导通路介导的疾病的方法。
• Aryl Ureas With Angiogenisis Inhibiting Activity
  申请人：Dumas Jacques

  公开号：US20080227828A1

  公开（公告）日：2008-09-18

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类化合物治疗由VEGF诱导的信号转导通路介导的异常血管生成或高渗透过程引起的疾病的方法。
• ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：DUMAS Jacques

  公开号：US20120289552A1

  公开（公告）日：2012-11-15

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类化合物治疗由VEGF诱导的信号转导通路介导的以异常血管生成或高渗透过程为特征的疾病的方法。
• Aryl ureas with angiogenesis inhibiting activity
  申请人：Bayer Healthcare LLC

  公开号：EP2324825A1

  公开（公告）日：2011-05-25

  This invention relates to the use of aryl ureas in the manufacture of a medicament for treating or preventing diseases characterized by abnormal angiogenesis or hyperpermeability processes which are mediated by the VEGF induced signal transduction pathway.

  本发明涉及使用芳基脲类制造一种药物，用于治疗或预防以血管内皮生长因子诱导的信号转导通路介导的异常血管生成或高渗透性过程为特征的疾病。